1887
Preview this article:
Zoom in
Zoomout

Evaluation of activity of recombinant lysostaphin against isolates of meticillin-resistant from Indian hospitals, Page 1 of 1

| /docserver/preview/fulltext/jmm/63/5/763_jmm070557-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.070557-0
2014-05-01
2020-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/5/763.html?itemId=/content/journal/jmm/10.1099/jmm.0.070557-0&mimeType=html&fmt=ahah

References

  1. Browder H. P., Zygmunt W. A., Young J. R., Tavormina P. A.. ( 1965;). Lysostaphin: enzymatic mode of action. . Biochem Biophys Res Commun 19:, 383–389. [CrossRef][PubMed]
    [Google Scholar]
  2. Christensen G. D., Simpson W. A., Younger J. J., Baddour L. M., Barrett F. F., Melton D. M., Beachey E. H.. ( 1985;). Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. . J Clin Microbiol 22:, 996–1006.[PubMed]
    [Google Scholar]
  3. CLSI ( 1999;). Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. M26-A. . Wayne, PA:: Clinical and Laboratory Standards Institute;.
  4. CLSI ( 2009a;). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, 10th edn. M02-A10. . Wayne, PA:: Clinical and Laboratory Standards Institute;.
  5. CLSI ( 2009b;). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 8th edn. M07-A8. . Wayne, PA:: Clinical and Laboratory Standards Institute;.
  6. Dajcs J. J., Hume E. B., Moreau J. M., Caballero A. R., Cannon B. M., O’Callaghan R. J.. ( 2000;). Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. . Invest Ophthalmol Vis Sci 41:, 1432–1437.[PubMed]
    [Google Scholar]
  7. Hill R. L. R., Kearns A. M., Nash J., North S. E., Pike R., Newson T., Woodford N., Calver R., Livermore D. M.. ( 2010;). Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. . J Antimicrob Chemother 65:, 442–445. [CrossRef][PubMed]
    [Google Scholar]
  8. Jones J. C., Rogers T. J., Brookmeyer P., Dunne W. M. Jr, Storch G. A., Coopersmith C. M., Fraser V. J., Warren D. K.. ( 2007;). Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. . Clin Infect Dis 45:, 541–547. [CrossRef][PubMed]
    [Google Scholar]
  9. Khatri G. S., Sharma R.. ( 2005;). Expression of recombinant matures lysostaphin. US Patent 6,897,041 B1. .
  10. Kokai-Kun J. F., Walsh S. M., Chanturiya T., Mond J. J.. ( 2003;). Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. . Antimicrob Agents Chemother 47:, 1589–1597. [CrossRef][PubMed]
    [Google Scholar]
  11. Mangili A., Bica I., Snydman D. R., Hamer D. H.. ( 2005;). Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. . Clin Infect Dis 40:, 1058–1060. [CrossRef][PubMed]
    [Google Scholar]
  12. McCoy M.. ( 2004;). Killing staph together: start-up Biosynexus places fermentation project at newly started Avecia facility. . Chem Eng News 82:, 36–40.
    [Google Scholar]
  13. Mirza Z. M., Kumar A., Kalia N. P., Zargar A., Khan I. A.. ( 2011;). Piperine as an inhibitor of the MdeA efflux pump of Staphylococcus aureus. . J Med Microbiol 60:, 1472–1478. [CrossRef][PubMed]
    [Google Scholar]
  14. Patron R. L., Climo M. W., Goldstein B. P., Archer G. L.. ( 1999;). Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. . Antimicrob Agents Chemother 43:, 1754–1755.[PubMed]
    [Google Scholar]
  15. Recsei P. A., Gruss A. D., Novick R. P.. ( 1987;). Cloning, sequence, and expression of the lysostaphin gene from Staphylococcus simulans. . Proc Natl Acad Sci U S A 84:, 1127–1131. [CrossRef][PubMed]
    [Google Scholar]
  16. Schindler C. A., Schuhardt V. T.. ( 1964;). Lysostaphin: a new bacteriolytic agent for the staphylococcus. . Proc Natl Acad Sci U S A 51:, 414–421. [CrossRef][PubMed]
    [Google Scholar]
  17. von Eiff C., Kokai-Kun J. F., Becker K., Peters G.. ( 2003;). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. . Antimicrob Agents Chemother 47:, 3613–3615. [CrossRef][PubMed]
    [Google Scholar]
  18. Walencka E., Sadowska B., Rozalska S., Hryniewicz W., Rózalska B.. ( 2005;). Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. . Pol J Microbiol 54:, 191–200.[PubMed]
    [Google Scholar]
  19. Yang X. Y., Li C. R., Lou R. H., Wang Y. M., Zhang W. X., Chen H. Z., Huang Q. S., Han Y. X., Jiang J. D., You X. F.. ( 2007;). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. . J Med Microbiol 56:, 71–76. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.070557-0
Loading
/content/journal/jmm/10.1099/jmm.0.070557-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error